Updates are available Correction dated 2025-03-18

Article History

Received: 28 January 2022

Accepted: 1 August 2022

First Online: 8 September 2022

Change Date: 18 March 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00259-025-07195-1

Declarations

:

: Animal work: All experiments were performed according to the guidelines of the local Animal Use and Care Committee (Government of Upper Bavaria, Numbers 55.2-1-54-2531-156-07, -2-10, 46-14) and are reported following the ARRIVE 2 guidelines.Human studies: This study was designed as a retrospective observational cohort study. Data collection, processing, and analysis were approved by our institutional ethics committee (Ethics Commission of the Faculty of Medicine of the Technical University of Munich, protocol number 180/17). The requirement for consent was waived. Informed consent was obtained from all individual participants included in the study. All procedures were carried out in accordance to pertinent laws and regulations.

: All authors declare they have no financial interests, except:1. J.T.S. reports research funding from BMS, Celgene and Roche/Genentech, consulting and personal fees from AstraZeneca, Bayer, BMS, Falk Foundation, Immunocore, MSD Sharp Dohme, Novartis, Roche, Servier and holds ownership in Pharma15 (all outside the submitted work).2. Wilko Weichert has attended Advisory Boards and served as speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK, and Molecular Health. WW receives research funding from Roche, MSD, BMS, and AstraZeneca (all outside the submitted work).